Nurix Therapeutics files $300M at-the-market stock offering via Piper Sandler

Nurix Therapeutics, Inc.

Amendment No.2 to Equity Distribution Agreement authorizes up to $300M aggregate gross offering price of common stock in ATM offerings.
Piper Sandler receives up to 3.0% sales commission on gross proceeds; expenses reimbursed up to $50K for this amendment.
Offering uses existing automatic shelf registration statement (File No. 333-280117) and prospectus supplement dated Oct 31, 2024.
No specific use of proceeds disclosed in the filing; proceeds will be net of commissions and expenses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.